摘要
目的:对结直肠癌患者在采用腹腔镜手术的基础上给予新辅助化疗方案进行治疗,探讨该方案对患者血清癌胚抗原(CEA)、CA242、CA19-9、CA724、细胞间黏附分子-1(ICAM-1)及血管细胞黏附分子-1(VCAM-1)水平的影响。方法 :回顾性分析自2012年1月至2015年1月我院收治的120例结直肠癌患者,分为对照组和观察组,每组60例患者。所有患者给予腹腔镜手术治疗,观察组患者在腹腔镜手术前给予新辅助化疗(FOLFOX4方案)4个周期,于治疗前后清晨取患者空腹静脉血进行离心处理,运用ELISA法检测两组患者血清CA242、CA19-9、ICAM-1及VCAM-1水平并进行比较,运用MEIA法检测两组患者血清CEA水平并进行比较,运用ECLI法检测两组患者血清CA724水平并进行比较。结果:(1)治疗前,两组患者血清CEA、CA242、CA19-9及CA724水平之间无显著性差异(P>0.05);治疗后,与同组治疗前相比,两组患者血清CEA、CA242、CA19-9及CA724水平均明显降低,差异具有显著性(P<0.05),且观察组患者血清CEA、CA242、CA19-9及CA724水平降低程度均明显优于对照组,两组之间具有显著性差异(P<0.05);(2)治疗前,两组患者血清ICAM-1、VCAM-1水平之间无显著性差异(P>0.05);治疗后,与同组治疗前相比,两组患者血清ICAM-1、VCAM-1水平均明显降低,差异具有显著性(P<0.05),且观察组患者血清ICAM-1、VCAM-1水平降低程度均明显优于对照组,两组之间具有显著性差异(P<0.05)。结论:对结直肠癌患者采用新辅助化疗联合腹腔镜手术的治疗方案能够有效降低血清CEA、CA242、CA19-9、CA724、ICAM-1及VCAM-1水平,该方案可通过调节癌症相关的肿瘤标志物及相关因子的表达,促进患者自身免疫系统的恢复,缓解患者病情,安全可靠,值得临床推广应用。
Objective： To observe the effects of neoadjuvant chemotherapy on the basis of laparoscopie operation on coloreetal carcinoma patients, serum CEA, CA242, CA19-9, CA724, ICAM-1 and VCAM-1 levels. Methods： A total of 120 cases of eolorectal carcinoma in our hospital from January 2012 to January 2015 were retrospectively analyzed and divided into control group and observation group, with each group of 60 patients. All patients were given laparoscopic operation, and the patients in the observation group were given neoadjuvant chemotherapy （FOLFOX4 regimen） four cycles before laparoscopic surgery, and fasting venous blood was taken and centrifuged before and after treatment in the morning. The serum CA242, CA19-9, ICAM-1 and VCAM-1 levels were measured by ELISA, the serum CEA levels were measured by MEIA, and the ser- um CA724 levels were measured by ECLI, and then compared with those of the two groups. Results; （1） Before treatment, there was no statistically significant difference in the serum CEA, CA242, CA19 9 and CA724 levels between the two groups （P〉0.05）. After treatment, compared with the same group before treatment, the serum CEA, CA242, CA19-9 and CA724 levels of the two groups were significantly lower （P ~0.05）, and those levels of observation group were significantly better than the control group, there was significant difference between the two groups （P〈0.05）; （2） Before treatment, there was no statistically significant difference in the serum ICAM 1, VCAM-1 levels between the two groups （P 〉0.05）. After treat- ment, compared with the same group before treatment, the serum ICAM-1, VCAM-1 levels of the two groups were signifi- cantly lower （P〈0.05）, and those levels of observation group were significantly better than the control group, there was sig- nificant difference between the two groups （P〈0.05）. Conclusions： The treatment of colorectal cancer patients with neoadju- vant chemotherapy combined with laparoscopic operation can effectively reduce serum CEA, CA242, CA19-9, CA724, ICAM- 1 and VCAM-1 levels, which indicates that the program can regulate cancerelated tumor markers and the expression of rela- tive factors, promote the recovery of patients with autoimmune system and ease the patient＇s condition. It is safe and reliable, worthy of clinical application.
出处
《海南医学院学报》
CAS
2017年第15期2094-2097,2101,共5页
Journal of Hainan Medical University
基金
河北省2015年度医学科学研究重点项目(ZL20150567)
关键词
腹腔镜手术
新辅助化疗
直肠癌
血清指标
Laparoscopic operatiom Neoadjuvant chemotherapy
Colorectal carcinoma
Serum paramete
